TODAY'S HEADLINES

Major diabetes drug cuts heart attack risk

New data from Novo Nordisk will help its Victoza type 2 diabetes drug better compete with Eli Lilly and Boehringer Ingelheim's Jardiance. Read more

Leukemia drug gets US okay, struggles in UK

While FDA just approved Imbruvica to treat patients with chronic lymphocytic leukemia (CLL), a UK organization refuses to recommend the drug. Read more

CONTINUING PHARMACY EDUCATION

Part 2: Law: Educating and empowering patients and caregivers: The pharmacist's role in reducing the risk of opioid overdose

This month's CE activity is open for pharmacists and pharmacy technicians. "Part II: Law: Educating and empowering patients and caregivers: The pharmacist's role in reducing the risk of opioid overdose." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

First chemotherapy antidote available soon

Vistogard – the first and only antidote for patients following an overdose of chemotherapy for adult and pediatric patients – will soon be available in the United States. Details

March 11, 2016

Related Articles

Diabetes drug may reduce stroke, CV deaths

FDA expands Opdivo use for metastatic melanoma